A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

摘要: Abstract Purpose This multi-institutional phase II trial assessed the activity and toxicity of a new histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid—SAHA) in patients with recurrent or persistent epithelial ovarian primary peritoneal carcinoma. Patients methods Women carcinoma who were platinum-resistant/refractory (progression-free interval Results Twenty-seven women enrolled through Gynecologic Oncology Group (GOG) on planned first stage accrual for this eligible analysis. Two survived progression-free over 6 months, one having partial response. grade 4 toxicities reported (one leukopenia neutropenia). The most common 3 constitutional (3/27; 11%) gastrointestinal (3/27, 11%). Other included neutropenia, metabolic abnormalities, thrombocytopenia (two each, 7%) as well neurologic complaints pain (1 patient each; 4%). Conclusion Vorinostat is tolerated but had minimal single agent unscreened platinum-refractory